254 related articles for article (PubMed ID: 30488098)
1. Prognostic value of baseline metabolic tumor volume measured on
Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098
[TBL] [Abstract][Full Text] [Related]
2.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
[TBL] [Abstract][Full Text] [Related]
4.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
Iravani A; Wallace R; Lo SN; Galligan A; Weppler AM; Hicks RJ; Sandhu S
Radiology; 2023 May; 307(3):e221180. PubMed ID: 36853183
[TBL] [Abstract][Full Text] [Related]
6. Absolute number of new lesions on
Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 2-[
Schweighofer-Zwink G; Manafi-Farid R; Kölblinger P; Hehenwarter L; Harsini S; Pirich C; Beheshti M
Eur J Radiol; 2022 Jan; 146():110107. PubMed ID: 34922117
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing
Reinert CP; Gatidis S; Sekler J; Dittmann H; Pfannenberg C; la Fougère C; Nikolaou K; Forschner A
Cancer Imaging; 2020 Jul; 20(1):44. PubMed ID: 32631431
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
12. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
13. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
[TBL] [Abstract][Full Text] [Related]
14. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
16. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.
Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA
Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852
[TBL] [Abstract][Full Text] [Related]
17. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
19. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]